Most Center for Drug Evaluation and Research offices outside of oncology are likely to stick with separate FDA and sponsor briefing documents for advisory committees rather than a single joint document that the cancer review divisions have embraced, Office of New Drugs Director Peter Stein said at the Biopharma Congress on 26 February.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?